{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-105729","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2022-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.285549+00:00","generated_at":"2026-06-26T07:26:12.145861+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pyxis Oncology CSO Ronald Herbst resigns; Jan Pinkas promoted to CSO","bullets":["Ronald Herbst, Ph.D. resigned as CSO effective April 12, 2022; Mark Chin resigned from Board same day.","Jan Pinkas, Ph.D., formerly SVP Preclinical R&D, promoted to CSO effective April 12, 2022.","Company reaffirms IND filings for PYX-201 (Anti-EDB) and PYX-106 (Anti-Siglec-15) expected in 2H22.","Neither departure was due to any disagreement with the company or Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-105729","json":"https://secwatch.observer/filing/0001193125-22-105729.json","markdown":"https://secwatch.observer/filing/0001193125-22-105729.md","text":"https://secwatch.observer/filing/0001193125-22-105729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000119312522105729/0001193125-22-105729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000119312522105729/d331497d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:26:12.145861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e935ab5d8","claim":"Ronald Herbst resigned as Chief Scientific Officer at Pyxis Oncology, Inc..","evidence_excerpt":"On April 8, 2022, Ronald Herbst, Ph.D. resigned from his position with Pyxis Oncology, Inc. (the “Company”) as Chief Scientific Officer, effective on April 12, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312522105729/0001193125-22-105729-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"ddf9952ec4","claim":"Mark Chin resigned as Director at Pyxis Oncology, Inc..","evidence_excerpt":"On April 12, 2022, Mark Chin resigned from his position as a director of the board of directors (the “Board”) of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312522105729/0001193125-22-105729-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}